NLRP3 and leukemia: Furthermore, we explored the role of NLRP3 inflammasome activation in AML chemotherapy, and found that the killing effect of ADR or DNR on leukemia cells was reversed by LPS-induced NLRP3 activation (Figures 1H, I, Supplementary Figure 1D).